TNFRSF4 and neoplasm: Recent preclinicalwork, for example, has explored the possibility of using intratumorallyadministered mRNA encoding a fusion protein combining IL-12 with aCD137 agonist and a TGF-β antagonist and observed both therapeuticeffects in the treated tumor as well as abscopal effects.102 Similar approaches are currently undergoinginvestigation in humans, including a trial with mRNA encoding IL-23and IL-36γ along with OX40 ligand and a trial with mRNA encodingIL-12 (NCT03739931, NCT05539157).